CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$2.77 USD
+0.52 (23.11%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.72 -0.05 (-1.81%) 7:12 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CLGN 2.77 +0.52(23.11%)
Will CLGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLGN
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
CLGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLGN
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS | CLGN Stock News
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial ...
CLGN: Shareholder Sales Won't Benefit Company Directly | CLGN Stock News
CollPlant files to sell 1.27M ordinary shares for holders
CollPlant files to sell 1.27M ordinary shares for holders